Gabelli Upgrades Assertio Therapeutics (ASRT) to Buy
- Wall Street ends volatile week sharply higher
- AT&T (T) in Talks to Merge Media Assets with Discovery (DISCA) - WSJ
- Disney (DIS) Dips As Streaming Business Shows Signs of Slowing Down, Analysts 'Very Bullish' on LT Opportunity
- Airbnb (ABNB) Bookings Up 52% to Help Sales Beat, Seen as a 'Blow Out Quarter' as More Upside is Left
- DoorDash (DASH) Reports Bigger Loss and a Sales Beat, Shares Soars on Strong Guidance and Two Upgrades to 'Buy'
Gabelli analyst Kevin Kendra upgraded Assertio Therapeutics (NASDAQ: ASRT) from Hold to Buy.
Shares of Assertio Therapeutics closed at $0.59 yesterday.
You May Also Be Interested In
- Ladenburg Thalmann Upgrades GrowGeneration (GRWG) to Buy
- Wells Fargo Upgrades Kimberly Clark (KMB) to Equal Weight
- UPDATE: Wells Fargo Upgrades Airbnb Inc. (ABNB) to Overweight, 'Ready for a Long-Term Stay'
Create E-mail Alert Related CategoriesUpgrades
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!